FY2024 · ended Dec 31, 2024 · Revenue $26,000, +0.0% YoY · Filed Mar 2, 2026
Viskase Holdings, Inc. (VISK) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Sep 30, 2026 it held $7.7 million in cash and investments and $290.6 million in total debt.
Revenue (TTM)
$271.95M
Net income (TTM)
$25.25M
+153.9% vs year-ago TTM
Operating cash flow (TTM)
$-42.57M
-434.7% vs year-ago TTM
Free cash flow
$8.43M
EPS (TTM)
$0.29
+114.2% vs year-ago TTM
Dividend per share
$2.00
Shares outstanding
14.33M
-80.7% vs prior year
Net cash
$-282.88M
as of Sep 30, 2026
Operating margin
4.2%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VISK (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Lombard, IL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 727510
- Former names
- ENZON PHARMACEUTICALS, INC. (until Mar 25, 2026); ENZON PHARMACEUTICALS INC (until Feb 23, 2016); ENZON PHARMACEUTICALS INC (until Mar 22, 2006); ENZON PHARMACEUTICAL INC (until Dec 10, 2002); ENZON INC (until Dec 9, 2002)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $26,000 | — | $26,000 | $701,000 |
| Operating income | -$5.3M | -$1.3M | -$1.0M | -$1.0M | -$469,000 |
| Net income | -$3.4M | $778,000 | $1.4M | -$186,000 | -$469,000 |
| Diluted EPS | -$0.07 | -$0.01 | $0.00 | -$0.02 | -$0.03 |
| Operating cash flow | -$3.0M | $1.1M | $1.3M | -$659,000 | -$501,000 |
| Total assets | $42.8M | $47.2M | $47.7M | $47.6M | $47.8M |
| Stockholders' equity | -$2.5M | $3.0M | -$3.5M | $3.4M | $4.9M |
| Cash and investments | $42.6M | $46.9M | $47.0M | $47.0M | $47.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
May 5, 2026 | Apr 30, 2026 |
| 10-Q | Quarterly report | May 4, 2026 | Mar 31, 2026 |
| 8-K/A | Amended current report | May 1, 2026 | Mar 26, 2026 |
| 8-K |
Current report
Officer or director change
|
May 1, 2026 | Apr 29, 2026 |
All 1000 Viskase Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.